Isesengura rya EGFR na ALK mu gusuzuma no kuvura neza NSCLC yo mu cyiciro cya mbere Hashingiwe ku Mabwiriza ya ESMO 2025

I. Incamake y'ibikubiye muriESMOUbuyobozi bw'umwaka wa 2025

Muri Kanama 2025, ESMO yasohoye ku mugaragaro ikinyamakuru cya mbere cya kanseri y'ibihaha itari iy'uturemangingo duto: ESMO Clinical Practice Guideline for diagnosis, treatment and following cancer, published in the top cancer Annals of Oncology. Iyi ni yo nkuru ya mbere yuzuye kuva mu 2017 kandi itanga imfashanyigisho zemewe cyane ku baganga b'indwara za kanseri ku isi yose.

Kanseri y'ibihaha ni yo ifite umubare munini w'abantu barwara kanseri ku isi. Buri mwaka, hari abantu barenga miliyoni 2.2 bandura kanseri nshya n'abarenga miliyoni 1.8 bapfa, ibi bigatuma kanseri y'ibihaha iba impamvu ikomeye y'impfu ziterwa na kanseri ku bagabo n'abagore. Kanseri y'ibihaha itari iy'uturemangingo duto (NSCLC) ifata abantu bagera kuri 80-85% by'abarwayi bose ba kanseri y'ibihaha. Muri iki kibazo gikomeye, isohoka ry'amabwiriza yo mu 2025 rishyira imbaraga nshya mu buvuzi, aho kuvugurura ingamba zo gupima biomarker ari ingenzi cyane. 

II. Gusobanura Ivugurura ry'Amabwiriza y'ingenzi

2.1 Isuzuma ry'ibimenyetso by'umubiri: Kuva ku "Byifuzwa" kugeza ku "Byifuzwa"

Amabwiriza yo mu 2025 atanga impinduka zikomeye ku bijyanye no gupima biomarker. Aya mabwiriza avuga neza ko gupima biomarker ari ingenzi kugira ngo hafatwe icyemezo cyo kuvura abarwayi bafite icyiciro cya IB-III NSCLC.

Iyi nama yongera uburyo bwo gupima ingirabuzimafatizo kuva ku barwayi barwaye indwara zikomeye kugeza ku barwaye indwara zo mu cyiciro cya mbere bashobora kuvurwa. Intego nyamukuru ni ukumenya impinduka mu ngirabuzimafatizo no gutanga ishingiro rya siyansi ryo kuvura neza. Iyi nama kandi ishimangira ko ubushobozi bwo gusuzuma ingirabuzimafatizo n'uburyo bwo gusuzuma bugomba kugenwa n'itsinda ry'abantu batandukanye hashingiwe ku miterere y'umurwayi n'imiterere ye.

Ku bijyanye n'ingamba zihariye zo gupima, amabwiriza asaba neza ko ibizamini bya gene bikorwa mbere yo gufata icyemezo cyo kubaga, kandi ko byibuze bigomba gukorerwa EGFR na ALK. Iki gitekerezo cyo "gupima mbere" gifite akamaro kanini mu buvuzi ku bijyanye no gushyira mu byiciro no kuvura byihariye NSCLC yo mu cyiciro cya mbere - igihe n'ukuri by'ibisubizo by'ibizamini ni byo bigena uburyo bwo guhitamo uburyo bwo kuvura bukurikira.

2.2 Impinduka mu buvuzi muri NSCLC yo mu cyiciro cya mbere cy’indwara ya Driver-Oncogene

Amabwiriza yo mu 2025 ahuza ibimenyetso byavuye mu bushakashatsi bwinshi bw’ingenzi bwo kwa muganga kugira ngo hashyirweho uburyo bwo kuvura neza abarwayi bafite NSCLC yo mu cyiciro cya mbere bafite uburwayi bwa kanseri y’umushoferi.

Abarwayi banduye indwara ya EGFR yahindutse:Hashingiwe ku igerageza ry’ingenzi rya ADAURA, nyuma yo kubagwa, umuti wa osimertinib ufasha mu kwivuza umaze imyaka itatu ubaye igipimo mpuzamahanga cy’ubuvuzi ku barwayi bafite EGFR exon 19 deletions cyangwa exon 21 L858R mutations. Igerageza rya ADAURA ni inyigo mpuzamahanga, ikorerwa mu byiciro byinshi, ikorwa ku buryo butaziguye, igenzura icyiciro cya gatatu, isuzuma imikorere n’umutekano wa osimertinib ufasha mu kwivuza ku barwayi bafite NSCLC yahinduwe burundu ya IB-IIIA EGFR. Ubushakashatsi bwagaragaje ko osimertinib yazamuye cyane ubuzima buzira indwara ndetse n’ubuzima muri rusange ugereranije na placebo, ishyiraho osimertinib nk'igipimo gishya cy’ubuvuzi kuri aba bantu. Ariko, isesengura ry’ubushakashatsi ryakozwe ku igerageza rya ADAURA ryagaragaje ko hafi 36% by’abahagaritse kuvurwa hakiri kare baterwaga n’ingaruka mbi, naho abandi 31% baterwaga n’umwanzuro w’umurwayi. Ibi bigaragaza ko hakenewe ibizamini by’ibanze bifatika mbere yo kuvurwa kugira ngo harebwe ko ubuvuzi bugenewe abarwayi bashobora kubona inyungu zirambye.

Abarwayi banduye ALK:Hashingiwe ku igerageza rya ALINA, alectinib yo mu rwego rwo hejuru nyuma yo kubagwa mu gihe cy'imyaka ibiri ubu ni yo ikoreshwa mu kwita ku barwayi. Mu isesengura ry'ibanze ry'igerageza rya ALINA ry'icyiciro cya gatatu, alectinib yagaragaje inyungu igaragara yo kurokoka mu cyiciro cya kabiri-IIIA cy'abaturage, aho igipimo cy'ibyago cya 0.24. Amakuru yavuguruwe yavuye mu igerageza rya ALINA yatanzwe mu nama ya ESMO 2025 yagaragaje ko nyuma y'imyaka ≥3 yo gukurikirana, inyungu ya DFS ya alectinib yakomeje "gukomeza kandi ifite akamaro mu buvuzi," aho igipimo cy'ibyago cya 0.36 cy'abaturage bo mu cyiciro cya kabiri-IIIA cy'abaturage. Igipimo giheruka cy'imyaka 4 yo kurokoka muri rusange cyageze kuri 98.4%, igipimo cya DFS cy'imyaka 4 cyari 75.5%, naho DFS yo mu bwonko nayo yarushijeho kunozwa, nta bimenyetso bishya by'umutekano. Aya makuru akomeye akomeza kwemeza alectinib yo mu rwego rwo hejuru nk'igipimo cy'ubuvuzi nyuma yo gucibwa ALK-positive NSCLC kandi ashimangira akamaro ko gupima neza kugira ngo hamenyekane abo barwayi.

Amahitamo y'uburyo bwo gupima:Amabwiriza ya ESMO yo mu 2025 agaragaza nezaisuzuma rya multiplex RT-PCR panelhamwe na NGS, IHC, na FISH bishingiye kuri RNA nk'imwe mu nzira za tekiniki zisabwa zo gupima ALK. Ibi bigaragaza ko icyo amabwiriza asabwa cyane ari ugukora ibizamini kugira ngo biyobore ibyemezo by'ubuvuzi, aho gutegeka urubuga runaka rwo gupima. Ku bicuruzwa bya RT-PCR byibanda ku gupima EGFR na ALK, iyi ngamba yo gupima ihindagurika itanga impamvu ikomeye ishingiye ku mabwiriza yo kubikoresha mu buvuzi.

III. Ibisubizo bya tekiniki byo gupima neza

Amabwiriza yo mu 2025 ashyira igeragezwa mu cyiciro cyo gufata ibyemezo mbere yo kubagwa, ibyo bikaba byongera ubushobozi bwo kumenya neza uburyo isuzuma rikorwa, uburyo rikorwa, n'uburyo rikorwa. Ibikoresho bibiri byo gupima bishingiye kuri RT-PCR bivugwa hano hepfo bihuye neza n'ibyo amabwiriza asabwa mu rwego rwa tekiniki.

3.1 EGFR Mutation Detection Kit – Urubuga rw’ikoranabuhanga rwa ARMS rwongerewe

Ikoranabuhanga ry'ibanze: Ikoranabuhanga rya ARMS rirushijeho kunozwa rituma habaho kongera imiterere y’ibintu bidahinduka mu buryo buhanitse mu buryo buhanitse mu buryo buhanitse.

Uburinzi butatu bwa tekiniki:

-Iterambere rya ARMS → rituma habaho kumenya impinduka mu mikorere y'umubiri (mutations)

-Kunoza enzyme → isesengura inyuma y’ubwoko bw’ishyamba kandi ikongera imiterere y’uturemangingo tw’impinduka

-Guhagarika ubushyuhe → bigabanya kwiyongera kw'ingufu ku buryo budasanzwe

Imikorere: Ubushobozi bwo kumva nezaIngano ya 1% ya allele yahinduwe

Kurwanya ubwandu: Igenzura ry'imbere ryubatswemo + enzyme ya UNG irinda kwanduzanya

Igihe cyo guhindura isura: Imikorere y'imiyoboro ifunze, hafiIminota 120

Ingero z'uburyo bwo guhuza:Ingingo/isuzuma ry'amaziingero → isuzuma ibisabwa "gupima mbere y'igihe"

Uburinzi:Impinduka 45muri EGFR exons 18-21, bihuye neza n'uturere twagaragajwe n'amabwiriza (exon 19 deletions na exon 21 L858R)

Gukoreshwa mu buvuzi: Iyobora mu buryo butaziguye ubuvuzi bwa EGFR-TKI

3.2 MMT EML4-ALK Fusion Detection Kit – Igisubizo cyo Gupima Fusion gishingiye kuri RNA

-Urubuga rw'ikoranabuhanga: RT-PCR ishingiye kuri RNA – itanga inyungu zisanzwe ugereranyije n'uburyo bushingiye kuri ADN bwo gupima fusion

-Akamaro gashingiye kuri RNA: Imenya mu buryo butaziguye inyandiko zakozwe zivanze, yirinda ingaruka mbi z'ibinyoma

-Inyigo y'ibimenyetso: Mu guhuza ALK nke, RT-PCR ni nziza cyane kurusha ibizamini bishingiye kuri ADN.

-Ubuhanga bwo kwiyumvisha ibintu: Imenya imikoranire kugeza kuKopi 20 kuri buri gisubizo

-Uburyo bwo gukwirakwiza ubwoko butandukanyeIbipfukishoUbwoko 12 busanzwe bwa EML4-ALK fusion(harimo ihinduka rya 1 ~ 33%; ihinduka rya 3a/3b hamwe ~ 29%)

-Imikorere n'igenzura ry'ihumana: Umuyoboro ufunze, ~iminota 120; uburyo bwo kugenzura ibikorwa byubatswemo + enzyme ya UNG birinda ibisubizo bitari byo

-Guhuza igikoresho: Ikorana n'ibikoresho bitandukanye bya PCR bikoreshwa mu gihe nyacyo

-Guhuza umurongo ngenderwaho: Bihuye cyane n'amabwiriza ya ESMO

IV. Ubwumvikane hagati y'ibizamini n'inama z'amabwiriza

Ibikoresho bibiri byo gupima bihuye cyane n'amabwiriza ya ESMO 2025 yo hambere kandi agezweho yo kurwanya kanseri y'ibihaha itari iy'uturemangingo duto mu nzego zikurikira:

V. Umwanzuro

Amabwiriza ya NSCLC yo mu cyiciro cya mbere cya ESMO 2025 azana igihe gishya cyo gusuzuma no kuvura neza, ashingiye ku “gupima mbere, kwibanda ku buryo bunoze, no kunoza uburyo bwo kuvura."EGFR Mutation Detection Kit na MMT EML4-ALK Fusion Detection Kit byujuje ibisabwa n'amabwiriza ku ntego, igihe, n'ubunyangamugayo binyuze mu nzira zitandukanye za tekiniki.

Akamashini ka EGFR gakoresha ikoranabuhanga rya ARMS rigezweho mu gupima impinduka zigamije mu buryo bwihuse mu bipimo bike, gashyigikira uburyo bwo gusuzuma ingirabuzima fatizo n'amazi kugira ngo "bikoreshwe mbere y'igihe."

Iyi kit ya ALK ishingiye kuri RT-PCR ishingiye kuri RNA, itanga inyungu kurusha uburyo bwa ADN bwo gupima fusion, ijyanye n'inama ya ESMO yo gukoresha paneli za multiplex RT-PCR zo gupima ALK.

Ibi bicuruzwa byombi hamwe, bigize igisubizo cyo gupima neza gikurikije amabwiriza ya ESMO 2025, gishyigikira uburyo bwo kuvura bwagenewe abantu ku giti cyabo kuri NSCLC yo mu cyiciro cya mbere.

Amareferensi:

1. Zer A, Ahn MJ, Barlesi F, n'abandi. Kanseri y'ibihaha itari iy'uturemangingo duto itangiye gukoreshwa mu ntangiriro kandi iteye imbere mu gace runaka: Ubuyobozi bwa ESMO mu gusuzuma, kuvura no gukurikirana. Ann Oncol. 2025;36(11):1245-1262. doi:10.1016/j.annonc.2025.08.003